2024/09/03 by Sarah Yusri, Weam Elbattawy, Salma Zaaya +3 · 1 citation
paper · doi:10.1111/jre.13344
crossref issued 2024/09/03 · crossref published 2024/09/03 · crossref published-online 2024/09/03 · crossref created 2024/09/03 · crossref published-print 2025/04/01 · crossref deposited 2025/06/05 · crossref indexed 2026/07/29
Abstract Aim Injectable platelet‐rich fibrin (I‐PRF), a second‐generation platelet concentrate, is widely used to enhance soft and hard tissue healing alone or in combination with biomaterials, relying on its harboring of various pivotal growth/differentiation factors. This randomized trial assessed the effect of clindamycin (CLN) augmented injectable platelet‐rich fibrin (I‐PRF) with modified minimally invasive surgical technique (M‐MIST) versus I‐PRF alone with M‐MIST on the clinical and radiographic parameters in the management of periodontal intra‐bony defects in patients with stage‐III grade B periodontitis. Methods This is a 9‐month parallel‐grouped, two arm, double‐blinded, randomized controlled trial (RCT) that included 28 patients ( n = 28) with stage‐III grade B periodontitis, who were allocated randomly to test‐ (CLN/I‐PRF + M‐MIST, 50 μL of CLN per 1 mL of I‐PRF; n = 14) or control‐group (I‐PRF + M‐MIST; n = 14). Clinical attachment level (CAL; primary outcome), probing depth (PD), gingival margin level (GML), plaque index (PI), and gingival index (GI) were recorded at baseline, 3, 6, and 9 months, whereas radiographic parameters radiographic linear defect depth (RLDD), and radiographic defect area (RDA) were recorded at baseline, 6, and 9 months. The CLN release kinetics from the I‐PRF were further characterized. Results Compared to baseline, both groups independently demonstrated significant improvements in CAL, PD, GML, GI, PI, RLDD and BDA at 3, 6 and 9 months ( p p p p > .05), GI significantly lower in CLN/I‐PRF + M‐MIST, whereas PD‐reduction significantly higher I‐PRF + M‐MIST group ( p Conclusions I‐PRF with M‐MIST provided significant clinical and radiographic improvement up to 9 months postoperatively in stage‐III grade B periodontitis. CLN, at the applied concentration and release duration, does not appear to further positively impact these observed I‐PRF effects.